| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Kevin Hern OK01 | 2 | −$40.5K | Trimmed Sep 2, 26 | |
| Julie Johnson TX32 | 1 | 3 | −$16.0K | Sold Dec 18, 25 |
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Sep 25, 25 |
| Thomas H. Kean Jr NJ07 | 2 | +$16.0K | Bought Sep 3, 25 | |
| Pete Sessions TX17 | 1 | −$75.0K | Sold Jun 12, 25 | |
| Rob Bresnahan PA08 | 1 | 2 | −$8.0K | Sold May 15, 25 |
| Jefferson Shreve IN06 | 1 | 2 | −$32.5K | Sold May 12, 25 |
| Julia Letlow LA05 | 1 | +$8.0K | Bought Apr 28, 25 | |
| Bruce Westerman AR04 | 1 | −$8.0K | Sold Apr 21, 25 | |
| Dan Newhouse WA04 | 1 | −$8.0K | Trimmed Apr 11, 25 | |
| Greg Landsman OH01 | 1 | −$8.0K | Sold Mar 27, 25 | |
| Gilbert Cisneros CA31 | 1 | −$8.0K | Trimmed Feb 26, 25 | |
| Valerie Hoyle OR04 | 1 | +$8.0K | Bought Oct 29, 24 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Sep 2, 26 | Kevin Hern OK01 | Joint | Sell (part) | $1,001 - $15,000 | Sep 25, 26 (23d) | |
| Aug 31, 26 | Kevin Hern OK01 | Joint | Sell | $15,001 - $50,000 | Sep 25, 26 (25d) | |
| Dec 18, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Jan 15, 26 (28d) | |
| Nov 13, 25 | Julie Johnson TX32 | Joint | Sell (part) | $1,001 - $15,000 | Dec 11, 25 (28d) | |
| Oct 7, 25 | Julie Johnson TX32 | Joint | Buy | $1,001 - $15,000 | Nov 14, 25 (38d) | |
| Sep 25, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Oct 22, 25 (27d) | |
| Sep 3, 25 | Thomas H. Kean Jr NJ07 | Self | Buy | $1,001 - $15,000 | Oct 14, 25 (41d) | |
| Jul 22, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (22d) | |
| Jun 12, 25 | Pete Sessions TX17 | Spouse | Sell | $50,001 - $100,000 | Jun 21, 25 (9d) | |
| Jun 11, 25 | Thomas H. Kean Jr NJ07 | Self | Buy | $1,001 - $15,000 | Jul 16, 25 (35d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 31, 25 (16d) | |
| May 12, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | Jun 22, 25 (41d) | |
| Apr 28, 25 | Julia Letlow LA05 | Self | Buy | $1,001 - $15,000 | Jan 13, 26 (260d) | |
| Apr 21, 25 | Bruce Westerman AR04 | Self | Sell | $1,001 - $15,000 | May 12, 25 (21d) | |
| Apr 11, 25 | Dan Newhouse WA04 | Spouse | Sell (part) | $1,001 - $15,000 | May 16, 25 (35d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Buy | $15,001 - $50,000 | May 8, 25 (30d) | |
| Apr 7, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | May 8, 25 (31d) | |
| Mar 27, 25 | Greg Landsman OH01 | Spouse | Sell | $1,001 - $15,000 | Apr 8, 25 (12d) | |
| Feb 26, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Mar 6, 25 (8d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Sell | $15,001 - $50,000 | Mar 27, 25 (30d) | |
| Jan 15, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Feb 12, 25 (28d) | |
| Oct 29, 24 | Valerie Hoyle OR04 | Spouse | Buy | $1,001 - $15,000 | Sep 12, 25 (318d) | |
| May 8, 15 | Jefferson Shreve IN06 | Self | Buy | $15,001 - $50,000 | Jun 22, 25 (3698d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Blair Rainer MChief Executive Officer | Sale at price 217.77 - 219.35 per share. | 58.3K | $12.74M |
| Aug 3, 2026 | Riley Christopher PaulOfficer | Stock Award(Grant) at price 0.00 per share. | 41.1K | — |
| Aug 3, 2026 | Gutierrez-Ramos Jose-CarlosOfficer | Stock Award(Grant) at price 0.00 per share. | 13.5K | — |
| Aug 3, 2026 | Milosevich Gregory MOfficer | Stock Award(Grant) at price 0.00 per share. | 15.4K | — |
| Aug 3, 2026 | Rales Steven MChairman of the Board | Stock Award(Grant) at price 0.00 per share. | 500K | — |
| Aug 3, 2026 | Rales Mitchell POfficer and Director | Stock Award(Grant) at price 0.00 per share. | 500K | — |
| Jul 14, 2026 | Zerhouni Elias ADirector | Conversion of Exercise of derivative security at price 71.88 per share. | 3.3K | $237.06K |
| Jul 14, 2026 | Filler LindaDirector | Conversion of Exercise of derivative security at price 71.88 per share. | 3.3K | $237.06K |
| May 14, 2026 | Dewan FerozDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Zerhouni Elias ADirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | List-Stoll Teri L.Director | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Sanders A.ShaneDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Filler LindaDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Stevens Raymond CDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Lamanna Charles WDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| May 14, 2026 | Spoon Alan GDirector | Stock Award(Grant) at price 0.00 per share. | 680 | — |
| Apr 30, 2026 | Spoon Alan GDirector | Sale at price 174.67 per share. | 1.4K | $237.21K |
| Apr 30, 2026 | Spoon Alan GDirector | Conversion of Exercise of derivative security at price 71.88 per share. | 3.3K | $237.06K |
| Feb 26, 2026 | Leiken Jonathan BOfficer | Stock Award(Grant) at price 0.00 per share. | 2.4K | — |
| Feb 26, 2026 | Gray Robert BradleyOfficer | Stock Award(Grant) at price 0.00 per share. | 2.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.4 | -3.8 | -10.0 | -5.6 | 2.1 | 4.3 | 2.4 | 9.5 | 3.7 | -0.2 | −3.4% | ||
| 2025 | -3.0 | -6.7 | -1.3 | -2.8 | -4.7 | 4.0 | -0.2 | 4.4 | -3.7 | 8.6 | 5.3 | 0.9 | −0.3% |
| 2024 | 3.7 | 5.5 | -1.4 | -1.2 | 4.1 | -2.7 | 10.9 | -2.8 | 3.2 | -11.6 | -2.4 | -4.2 | −0.8% |
| 2023 | -0.4 | -6.4 | 1.8 | -6.0 | -3.1 | 4.5 | 6.3 | 3.9 | -6.4 | -12.7 | 16.3 | 3.6 | −1.7% |
| 2022 | -13.1 | -4.0 | 6.9 | -14.4 | 5.1 | -3.9 | 15.0 | -7.4 | -4.3 | -2.6 | 8.6 | -2.9 | −19.3% |
| 2021 | 7.1 | -7.6 | 2.5 | 12.8 | 0.9 | 4.8 | 10.9 | 9.0 | -6.1 | 2.4 | 3.2 | 2.3 | +48.1% |
| 2020 | 4.8 | -10.1 | -4.3 | 18.1 | 1.9 | 6.1 | 15.3 | 1.3 | 4.3 | 6.6 | -2.1 | -1.1 | +44.7% |
| 2019 | 7.6 | 14.5 | 3.9 | 0.3 | -0.3 | 8.3 | -1.7 | 1.1 | 1.6 | -4.6 | 5.9 | 5.1 | +48.8% |
| 2018 | 9.1 | -3.5 | 0.1 | 2.5 | -1.0 | -0.6 | 4.0 | 0.9 | 4.9 | -8.5 | 10.2 | -5.9 | +11.1% |
| 2017 | 7.8 | 1.9 | -0.0 | -2.6 | 1.9 | -0.6 | -3.4 | 2.4 | 2.8 | 7.6 | 2.3 | -1.6 | +19.2% |
| 2016 | -6.7 | 3.0 | 6.3 | 2.0 | 1.7 | 2.7 | 6.4 | -0.0 | -3.7 | 0.2 | -0.5 | -0.4 | +10.5% |
| 2015 | -3.9 | 5.9 | -2.7 | -3.6 | 5.4 | -0.8 | 7.0 | -5.0 | -2.1 | 9.5 | 3.3 | -3.6 | +8.4% |
| 2014 | -3.6 | 2.8 | -1.9 | -2.2 | 6.9 | 0.4 | -6.2 | 3.7 | -0.8 | 5.8 | 3.9 | 2.6 | +11.0% |
| 2013 | 7.2 | 2.8 | 0.9 | -1.9 | 1.4 | 2.4 | 6.4 | -2.7 | 5.8 | 4.0 | 3.8 | 3.2 | +38.1% |
| 2012 | 11.6 | 0.6 | 6.0 | -3.2 | -4.1 | 0.2 | 1.4 | 1.4 | 2.9 | -6.2 | 4.3 | 3.6 | +18.8% |
| 2011 | -2.4 | 9.9 | 2.6 | 6.4 | -1.3 | -2.8 | -7.3 | -6.7 | -8.4 | 15.3 | 0.1 | -2.8 | −0.3% |
| 2010 | -5.1 | 3.7 | 8.0 | 5.5 | -5.8 | -6.5 | 3.5 | -5.4 | 11.8 | 6.8 | -0.3 | 9.1 | +25.5% |
| 2009 | -1.2 | -9.2 | 6.8 | 7.8 | 3.3 | 2.3 | -0.8 | -0.9 | 10.9 | 1.4 | 3.9 | 6.0 | +32.8% |
| 2008 | -14.6 | -1.1 | 2.5 | 2.6 | 0.2 | -1.1 | 3.0 | 2.4 | -14.9 | -14.6 | -6.1 | 1.7 | −35.5% |
| 2007 | 2.2 | -3.2 | -0.3 | -0.4 | 3.2 | 2.7 | -1.1 | 4.0 | 6.5 | 3.6 | 1.3 | 1.1 | +21.1% |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Buy / hold / sell counts